Chinese Medical Sciences Journal ›› 2013, Vol. 28 ›› Issue (2): 127-128.doi: 10.1016/S1001-9294(13)60036-X

• Case Report • Previous Articles    

Combination of Rapamycin and Imatinib in Treating Refractory Chronic Myeloid Leukemia Myeloid Blast Crisis:a Case Report025B3;

Jing Xie1, Xiang Zhang1, Bao-zhi Fang1, Guang-sheng He1, *, Yun Zhao2, De-pei Wu1   

  1. 1Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 2Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China
  • Revised:2012-10-22 Online:2013-06-26 Published:2013-06-26
  • Contact: 0002A;CorrespondingauthorTel/Fax:86-512-65113556,E-mail:heguangsheng@medmail.com.cn
  • Supported by:

    Supported by Key Provincial Talents Program of Jiangsu (H201126), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Key words: chronic myeloid leukemia, imatinib, imatinib-resistent, rapamycin, mammalian target of rapamycin

Copyright © 2018 Chinese Academy of Medical Sciences. All right reserved.
 
www.cmsj.cams.cn
京公安备110402430088 京ICP备06002729号-1  Powered by Magtech.

Supervised by National Health & Family Plan Commission of PRC

9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China

Tel: 86-10-65105897  Fax:86-10-65133074 

E-mail: cmsj@cams.cn  www.cmsj.cams.cn

Copyright © 2018 Chinese Academy of Medical Sciences

All right reserved.

京公安备110402430088  京ICP备06002729号-1